News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
110,781 Results
Type
Article (7121)
Company Profile (14)
Press Release (103646)
Multimedia
Podcasts (67)
Webinars (5)
Section
Business (41839)
Career Advice (392)
Deals (7453)
Drug Delivery (63)
Drug Development (10159)
Employer Resources (33)
FDA (1875)
Job Trends (1994)
News (60776)
Policy (4472)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (281)
Accelerated approval (8)
Adcomms (6)
Allergies (20)
Alliances (6075)
ALS (25)
Alzheimer's disease (217)
Antibody-drug conjugate (ADC) (71)
Approvals (1867)
Artificial intelligence (102)
Autoimmune disease (36)
Automation (7)
Bankruptcy (72)
Best Places to Work (1561)
BIOSECURE Act (3)
Biosimilars (44)
Biotechnology (14)
Bladder cancer (11)
Brain cancer (8)
Breast cancer (99)
Cancer (649)
Cardiovascular disease (89)
Career advice (345)
Career pathing (7)
CAR-T (44)
CDC (11)
Cell therapy (133)
Cervical cancer (4)
Clinical research (8554)
Collaboration (310)
Company closure (1)
Compensation (56)
Complete response letters (17)
COVID-19 (371)
CRISPR (9)
C-suite (377)
Cystic fibrosis (30)
Data (792)
Decentralized trials (1)
Denatured (3)
Depression (20)
Diabetes (195)
Diagnostics (940)
Digital health (11)
Diversity (2)
Diversity, equity & inclusion (12)
Drug discovery (59)
Drug pricing (101)
Drug shortages (23)
Duchenne muscular dystrophy (75)
Earnings (18469)
Editorial (29)
Employer branding (1)
Employer resources (31)
Events (12414)
Executive appointments (451)
FDA (2399)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (1)
Funding (299)
Gene editing (28)
Generative AI (14)
Gene therapy (134)
GLP-1 (639)
Government (745)
Grass and pollen (1)
Guidances (84)
Healthcare (3234)
HIV (4)
Huntington's disease (8)
IgA nephropathy (16)
Immunology and inflammation (47)
Immuno-oncology (16)
Indications (12)
Infectious disease (417)
Inflammatory bowel disease (41)
Inflation Reduction Act (6)
Influenza (19)
Intellectual property (58)
Interviews (46)
IPO (3212)
IRA (25)
Job creations (442)
Job search strategy (298)
JPM (19)
Kidney cancer (3)
Labor market (18)
Layoffs (105)
Leadership (9)
Legal (1138)
Liver cancer (11)
Longevity (4)
Lung cancer (88)
Lymphoma (31)
Machine learning (7)
Management (9)
Manufacturing (161)
MASH (67)
Medical device (2474)
Medtech (2491)
Mergers & acquisitions (4588)
Metabolic disorders (662)
Multiple sclerosis (21)
NASH (7)
Neurodegenerative disease (59)
Neuropsychiatric disorders (20)
Neuroscience (419)
Neurotech (1)
NextGen: Class of 2026 (1024)
Non-profit (459)
Now hiring (30)
Obesity (414)
Opinion (83)
Ovarian cancer (26)
Pain (39)
Pancreatic cancer (27)
Parkinson's disease (39)
Partnered (3)
Patents (100)
Patient recruitment (77)
Peanut (6)
People (17830)
Pharmaceutical (12)
Pharmacy benefit managers (10)
Phase 1 (2663)
Phase 2 (3923)
Phase 3 (3006)
Pipeline (1045)
Policy (106)
Postmarket research (211)
Preclinical (972)
Press Release (19)
Prostate cancer (30)
Psychedelics (15)
Radiopharmaceuticals (73)
Rare diseases (168)
Real estate (616)
Recruiting (16)
Regulatory (3414)
Reports (16)
Research institute (322)
Resumes & cover letters (51)
Rett syndrome (5)
RNA editing (2)
RSV (9)
Schizophrenia (47)
Series A (67)
Series B (38)
Service/supplier (1)
Sickle cell disease (22)
Special edition (6)
Spinal muscular atrophy (25)
Sponsored (9)
Startups (631)
State (1)
Stomach cancer (1)
Supply chain (32)
Tariffs (24)
The Weekly (63)
Vaccines (154)
Venture capital (29)
Weight loss (360)
Women's health (12)
Worklife (2)
Date
Last 7 days (128)
Last 30 days (408)
Last 365 days (5642)
2026 (706)
2025 (5700)
2024 (6799)
2023 (7098)
2022 (9815)
2021 (9961)
2020 (8991)
2019 (7041)
2018 (5538)
2017 (5368)
2016 (4939)
2015 (5627)
2014 (4220)
2013 (3231)
2012 (3486)
2011 (3655)
2010 (3274)
Location
Africa (125)
Alabama (14)
Alaska (3)
Arizona (49)
Arkansas (5)
Asia (7391)
Australia (1174)
California (1781)
Canada (720)
China (254)
Colorado (107)
Connecticut (99)
Delaware (53)
Europe (16959)
Florida (323)
Georgia (63)
Idaho (6)
Illinois (142)
India (11)
Indiana (125)
Iowa (2)
Japan (101)
Kansas (12)
Kentucky (3)
Louisiana (5)
Maine (7)
Maryland (278)
Massachusetts (1262)
Michigan (48)
Minnesota (82)
Missouri (12)
Montana (13)
Nebraska (7)
Nevada (15)
New Hampshire (26)
New Jersey (782)
New Mexico (7)
New York (447)
North Carolina (292)
Northern California (875)
Ohio (54)
Oklahoma (6)
Oregon (4)
Pennsylvania (342)
Puerto Rico (11)
Rhode Island (12)
South America (189)
South Carolina (5)
Southern California (681)
Tennessee (16)
Texas (306)
United States (6686)
Utah (40)
Virginia (25)
Washington D.C. (12)
Washington State (99)
West Virginia (1)
Wisconsin (16)
Wyoming (1)
110,781 Results for "novo holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Novo’s Wegovy Pill Success Is ‘Good News’ for Orforglipron, Lilly Execs Say
Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.
February 4, 2026
·
2 min read
·
Annalee Armstrong
Weight loss
Novo’s Next-Gen Obesity Drug Beats Wegovy on Blood Sugar Control in Phase III
While CagriSema bested Novo Nordisk’s Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma’s 25% weight loss goal.
February 3, 2026
·
2 min read
·
Tristan Manalac
Earnings
Novo Goes ‘All In’ on Wegovy Pill but Analysts Worry It’s Not Enough
Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.
February 4, 2026
·
3 min read
·
Annalee Armstrong
Editorial
Novo Will Never Beat Lilly. Why Does It Have To?
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
February 5, 2026
·
3 min read
·
Annalee Armstrong
Podcast
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
A lawsuit and FDA warning ensued after Hims & Hers launched a compounded version of Novo Nordisk’s new obesity pill, more Big Pharma report earnings—including from weight loss rivals Novo and Eli Lilly—and the gene therapy space sees another rejection.
February 11, 2026
·
1 min read
·
Jef Akst
Earnings
Novo Slides 14% as Early Q4 Results Predict Sales Decline for 2026
Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for this year.
February 3, 2026
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.
January 2, 2026
·
5 min read
·
Annalee Armstrong
GLP-1
Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race
Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.
December 23, 2025
·
2 min read
·
Nick Paul Taylor
GLP-1
Novo Sues Hims & Hers Over Compounded Version of Oral Wegovy Pill
Novo Nordisk has sued Hims for allegedly violating patents protecting semaglutide, seeking potentially “hundreds of millions” in damages, John Kuckelman, the pharma’s general counsel, said. The wellness platform pulled its version of the drug just days after launching it.
February 9, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Novo’s GLP-1 Fails to Slow Alzheimer’s, Sending Shares Down 10%
“We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, Novo’s R&D chief, said on Monday.
November 24, 2025
·
2 min read
·
Annalee Armstrong
1 of 11,079
Next
